<code id='1C0AE4C985'></code><style id='1C0AE4C985'></style>
    • <acronym id='1C0AE4C985'></acronym>
      <center id='1C0AE4C985'><center id='1C0AE4C985'><tfoot id='1C0AE4C985'></tfoot></center><abbr id='1C0AE4C985'><dir id='1C0AE4C985'><tfoot id='1C0AE4C985'></tfoot><noframes id='1C0AE4C985'>

    • <optgroup id='1C0AE4C985'><strike id='1C0AE4C985'><sup id='1C0AE4C985'></sup></strike><code id='1C0AE4C985'></code></optgroup>
        1. <b id='1C0AE4C985'><label id='1C0AE4C985'><select id='1C0AE4C985'><dt id='1C0AE4C985'><span id='1C0AE4C985'></span></dt></select></label></b><u id='1C0AE4C985'></u>
          <i id='1C0AE4C985'><strike id='1C0AE4C985'><tt id='1C0AE4C985'><pre id='1C0AE4C985'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:focus    - browse:6516
          Roche HQ
          SEBASTIEN BOZON/AFP via Getty Images

          The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

          Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

          advertisement

          The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          hotspot